INV-102

DRUG4 trials

Sponsors

Invirsa, Inc.

Conditions

Acute Infectious KeratoconjunctivitisCenter-involved Diabetic Macular EdemaCenter-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic RetinopathyDiabetic RetinopathyDry Eye DiseaseNon-center Involved Diabetic Macular EdemaNon-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Phase 1

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

CompletedNCT05586152

Invirsa, Inc.Dry Eye Disease

Start: 2022-08-30End: 2023-05-02Updated: 2026-09-18

Phase 2

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

CompletedNCT05636228

Invirsa, Inc.Acute Infectious Keratoconjunctivitis

Start: 2023-06-09End: 2024-08-22Updated: 2026-09-18

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

CompletedNCT06370039

Invirsa, Inc.Dry Eye Disease

Start: 2024-03-27End: 2024-07-03Updated: 2026-09-18

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

CompletedNCT06599684

Invirsa, Inc.Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy +2

Start: 2024-09-07End: 2025-09-30Updated: 2026-01-27